Pseudoxanthoma elasticum – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pseudoxanthoma elasticum – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy https://clinicaltrials.eu/trial/long-term-safety-study-of-inz-701-for-patients-with-enpp1-and-abcc6-deficiencies-including-pseudoxanthoma-elasticum-and-generalized-arterial-calcification-of-infancy/ Wed, 29 Apr 2026 14:58:53 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-inz-701-for-patients-with-enpp1-and-abcc6-deficiencies-including-pseudoxanthoma-elasticum-and-generalized-arterial-calcification-of-infancy/ This clinical trial is focused on studying the long-term safety of a treatment called INZ-701 for patients with certain rare conditions. These conditions include Pseudoxanthoma Elasticum (PXE), Generalized Arterial Calcification of Infancy (GACI), and deficiencies in Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6). These are genetic disorders that can cause problems with the skin, eyes, and blood vessels, among other symptoms.

The treatment being studied, INZ-701, is a type of medication that is given as an injection under the skin. It is a specially designed protein that aims to help manage these conditions. The study will follow participants who have already received INZ-701 in a previous clinical study to see how they respond to the treatment over a longer period.

Participants in this study will receive regular injections of INZ-701 and will be monitored for any side effects or changes in their health. The study will look at how often and how severe any side effects are, as well as any changes in laboratory tests. This information will help researchers understand the long-term safety of INZ-701 for people with these rare conditions.

]]> Study on Preventing Arterial Calcification in Young Patients with Pseudoxanthoma Elasticum Using Etidronate https://clinicaltrials.eu/trial/study-on-preventing-arterial-calcification-in-young-patients-with-pseudoxanthoma-elasticum-using-etidronate/ Wed, 29 Apr 2026 14:22:37 +0000 https://clinicaltrials.eu/trial/study-on-preventing-arterial-calcification-in-young-patients-with-pseudoxanthoma-elasticum-using-etidronate/ This clinical trial is focused on studying a rare genetic condition called Pseudoxanthoma Elasticum (PXE). PXE affects the skin, eyes, and blood vessels, leading to changes in the body’s connective tissues. The trial will investigate the effects of a treatment using Etidronate Disodium, which is a type of medication known as a bisphosphonate. This medication is being tested to see if it can prevent or slow down the buildup of calcium in the arteries, which is a common problem in people with PXE.

The purpose of the study is to determine if taking Etidronate Disodium for 24 months can stop the progression of calcium deposits in the arteries of the legs and neck. Participants in the study will be randomly assigned to receive either the Etidronate Disodium capsules or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, various tests will be conducted to monitor changes in the participants’ arteries and overall health. These tests include imaging techniques like computed tomography (CT) scans and ultrasound to measure calcium buildup and artery thickness. The study will also assess the impact of the treatment on eye health, skin condition, and overall quality of life. The trial aims to provide valuable insights into whether Etidronate Disodium can be an effective treatment for managing PXE and its associated complications.

]]>